

Esophageal Oncology group : Treatment map Jan.2026.

UICC 8th	Standard treatment in Japan		Trials ongoing or follow up	
Stage I (N0)	Endoscopic resection (ESD/EMR) + CRT		JCOG1904 CRT: IFI ⁵⁾ vs. ENI ⁶⁾ 2020/03~ Ongoing	
Stage I (N1)	Esophagectomy (Thoracoscopic or open esophagectomy) ¹⁾	Concurrent CRT (CF-RT ⁴⁾)	JCOG2013 (±NeoCF ²⁾ /DCF ³⁾) Esophagectomy: Upper and Middle thoracic Esophageal Squamous Cell Cancer SCLN ⁸⁾ Dissection vs Preservation 2022/8~ Ongoing	
Stage II	Neoadjuvant chemotherapy (Neo DCF ³⁾) + Esophagectomy (Thoracoscopic or open esophagectomy) ¹⁾	Adjuvant Nivolumab (After CRT + Esophagectomy)	JCOG2206 NeoCF ²⁾ /DCF ³⁾) + Esophagectomy: Surgery alone vs Nivolumab vs S-1 2023/7~ Ongoing	
Stage III		Concurrent CRT (CF-RT ⁴⁾) (+Salvage esophagectomy or endoscopic resection)	JCOG2203 Adenocarcinoma of EGJ ⁹⁾ Esophagectomy: Upfront surgery vs Neo DOS ¹⁰⁾ /FLOT ⁷⁾ 2023/7~ Ongoing	
T4a/M1LYM* Resectable	Neoadjuvant chemotherapy + Esophagectomy ¹⁾	Concurrent CRT	JCOG1510 Concurrent CRT vs. Induction DCF ³⁾) + Concurrent CRT or Esophagectomy 2018/2~ Follow up period	
T4b/M1LYM* Unresectable	Concurrent CRT			
Stage IVB	1 st line chemotherapy: CF ²⁾) + Pembrolizumab CF ²⁾) + Nivolumab CF ²⁾) + Tislelizumab	2 nd line chemotherapy: Paclitaxel Docetaxel If no previous ICIs ¹¹⁾ : Nivolumab, Tislelizumab, Pembrolizumab (CPS ≥10)	JCOG2311 Radiation therapy + Nivolumab + Ipilimumab vs. Nivolumab + Ipilimumab 2024/11~ Ongoing	
Recurrent				

*M1LYM due to supraclavicular lymph node only 1) 2-3 field lymph node dissection 2) CF, CDDP + 5-FU 3) DCF, DOC + CDDP + 5-FU 4) CF-RT, CDDP + 5-FU + radiation 5) IFI, Involved field irradiation 6) ENI, Elective lymph node irradiation 7) FLOT, 5-FU + LV + L-OHP + DOC 8) SCLN, Supraclavicular lymph node 9) EGJ, Esophagogastric junction 10) DOS, DOC + L-OHP + S-1 11) ICI, Immune checkpoint inhibitor